All In MedTech

Device Trial Radar · NCT02809690

18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer

Pilot Feasibility Study of 18F-FMAU PET for Diagnosing and Characterizing Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Sep 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

18

Actual

Start

Sep 12, 2016

Primary completion

Jul 21, 2021

Study completion Jul 21, 2021

Sponsor

Lead sponsor
University of Southern CaliforniaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI); National Institute for Biomedical Imaging and Bioengineering (NIBIB)
First posted
Jun 22, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This pilot clinical trial studies how well fluorine F 18 d-FMAU (18F-FMAU) positron emission tomography (PET)/computed tomography (CT) works in diagnosing and characterizing prostate cancer. A PET/CT scan is an imaging test that uses a small amount of radioactive tracer that is given through the vein to take detailed pictures of areas inside the body where the tracer is taken up. Radiotracers such as 18F-FMAU may help to find the cancer and see how far the disease has spread.

Conditions

  • Prostate Neoplasm

Interventions

  • CATDevice

    Undergo 18F-FMAU PET/CT

  • 18F-FMAUDrug

    Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • Multiparametric Magnetic Resonance ImagingProcedure

    Undergo mpMRI

  • Positron Emission TomographyDevice

    Undergo 18F-FMAU PET/CT

  • UltrasoundDevice

    Undergo TRUS-guided biopsy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of men for whom biopsy cores taken based only on the 18F-FMAU PET/CT results would have yielded the same overall diagnosis as the standard TRUS-guided core or the mpMRI-directed prostate biopsiesTime frame: Up to 1 year
  2. Proportion of men for whom the 18F-FMAU PET/CT identified all lesions that were found to have cancer based on the standard TRUS-guided and the mpMRI directed core prostate biopsiesTime frame: Up to 1 year
  3. Proportion of men who completed both imaging procedures and for whom biopsy cores taken based only on the fluorine 18F-FMAU PET/CT results would have yielded the same overall diagnosis as the standard TRUS-guided core prostate biopsiesTime frame: Up to 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.